Controversies Regarding Subclinical Leaflet Thrombosis After TAVR

Published: 25 February 2021

  • Views:

    Views Icon 925
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 2 | Session 2 of 3
    CONTRA
    Poonam Velagapudi
    Up Next
  • episode_image
    Part 2 | Session 3 Panel discussion & Audience Questions
    Jolanta Siller-Matula, Mamas A Mamas, Poonam Velagapudi, Kimberly Atianzar, Renate B Schnabel
  • episode_image
    Part 3 | Session 1 PRO
    Kimberly Atianzar
  • episode_image
    Part 3 | Session 2 CONTRA
    Renate B Schnabel
  • episode_image
    Part 3 | Session 3 Panel discussion & Audience Questions
    Jolanta Siller-Matula, Mamas A Mamas, Poonam Velagapudi, Kimberly Atianzar, Renate B Schnabel
  • episode_image
    Part 2 | Session 1 PRO Mamas A Mamas
Average (ratings)
No ratings
Your rating

Overview

A substantial number of patients develop a subclinical leaflet thrombosis (SLT) after transcatheter aortic valve replacement (TAVR).

The thrombus forms on the leaflets, which can lead to valve dysfunction and possibly to early valve degeneration. Multidetector computed tomography is the most sensitive imaging technique at detecting SLT.

Patients on antiplatelet drugs are at higher risk to develop SLT as compared to those on anticoagulants. During the live debate, the experts in the field will discuss controversies concerning SLT, including the routine use of oral anticoagulants and CT exams after TAVR.

Learning Objectives

  • To learn about the natural history, incidence and clinical implications of SLT
  • To learn about the mechanisms that may lead to SLT
  • To understand the diagnostic criteria SLT
  • To discuss the prevention and treatment options for SLT

Audience

  • Interventional cardiologists with focus on TAVR procedures
  • Cardiac Imaging specialists (Echocardiography, Computer Tomography)
  • General cardiologists
  • Specialists interested in management of antithrombotic therapies after TAVR

More from this programme

Part 1

Subclinical leaflet thrombosis after TAVR: Numbers and facts

Part 2

Debate: Patients should receive routine CT screening after TAVR to exclude subclinical valve thrombosis

Part 3

Debate: Patients should be routinely discharged on oral anticoagulants for prevention of subclinical valve thrombosis after TAVR

Faculty Biographies

Poonam Velagapudi

Poonam Velagapudi

Structural Interventional Cardiologist, Assistant Professor of Medicine and Associate Program Director for Cardiovascular Medicine fellowship at the University of Nebraska

Dr Poonam Velagapudi is a Structural Interventional Cardiologist, Assistant Professor of Medicine and Associate Program Director for Cardiovascular Medicine fellowship at the University of Nebraska. Her clinical interests include high risk PCI, mechanical circulatory support in shock, radial and large bore access, percutaneous transcatheter valve procedures including TAVR, TMVR, and MitraClip. She is a Fellow of the American College of Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions (SCAI), Chair of the ACC Early Career Section of the, Past Chair of the ACC Fellows in Training Section, and Co-Chair of the SCAI Educational Committee. Her focus is education, advocacy and increasing/promoting participation of women in clinical trials. She is a strong proponent of using social media for fostering education in cardiology and serves as the social media editor for JACC Interventions journal and Early Career Correspondent for ACC ACCEL Audio. She is an…

View full profile